SOPH · Categories · Conferences
SOPH - Conference and earnings call announcements
SOPHiA GENETICS SA (SOPH) conference and earnings call announcements - real-time wire coverage filtered to Conferences only.
Recent Conferences for SOPH
- Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.LONDON, May 13, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program. Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™. This innovative test, originally developed by Memorial Slo
- SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care ConferenceBOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday, March 4, 2026, at 10:30 am EST / 4:30 pm CET. A live audio webcast of the fireside chat will be available here. Additionally, a replay of the webcast will be available
- Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy TestingSOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
- SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth ConferenceBOSTON and ROLLE, Switzerland, Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD Cowen FutureHealth Conference in early September. Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 22nd Annual Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024, at 1:50 p.m. EDT. The following week, co-Founder and Chief Executive Officer, Dr. Jurgi Cambl
- SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceBOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT. The presentation will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine
- SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare ConferenceBOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT. The fireside chat will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a software company dedicated to establishing the practice of data-driven medicine a
- SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care ConferenceBOSTON and ROLLE, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Co-founder and Chief Executive Officer, Dr. Jurgi Camblong, and Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. EDT. The fireside chat will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a software company dedicat
- SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare ConferenceBOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ:SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco. Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentation. About SOPHiA GENETICSSOPHiA GENETICS (NASDAQ:SOPH) is a
- SOPHiA GENETICS to Present at the J.P. Morgan 2023 Healthcare ConferenceSOPHiA GENETICS SA (NASDAQ:SOPH) today announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco. Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentation. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native software company in the healthcare space dedicated
- SOPHiA GENETICS to Participate in Upcoming November Investor ConferencesBOSTON and LAUSANNE, Switzerland, Nov. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, announced today the company will be participating in the following investor conferences. Evercore ISI HealthCONx Virtual Conference; Fireside Chat on Tuesday, November 29 at 2:15pm EST / 8:15pm CETCredit Suisse 26th Annual Technology Conference in Scottsdale, AZ; Fireside Chat on Wednesday, November 30 at 1:40pm MST / 9:40pm CET Interested parties may access live and archived webcasts of the sessions on the Investor Relations section of the company website at ir.sophiagenetics.com. About SOPHiA GENETICSSOPHiA GENETICS (NASDAQ:SOPH
- SOPHiA GENETICS to Participate in Fireside Chat at 20th Annual Morgan Stanley Global Healthcare ConferenceBOSTON and LAUSANNE, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, announced today Chief Executive Officer, Dr. Jurgi Camblong and Chief Financial Officer, Ross Muken will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, at 8:45 a.m. EDT. About SOPHiA GENETICSSOPHiA GENETICS (NASDAQ:SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data
- SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth ConferenceBOSTON and LAUSANNE, Switzerland, July 29, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a leader in data-driven medicine, announced today Chief Financial Officer, Ross Muken, will attend and be a panelist at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at the InterContinental Hotel in Boston, MA, United States. Ross will join other industry leaders for the panel "Leveraging Omics-Based Data and Analytics to Advance Precision Health to the Next Level," starting at 9:30 a.m. EST. A live webcast and replay of the session will be available on the investor relations section of the SOPHiA GENETICS website at https://ir.sophiagenetics.com. Abou
- SOPHiA GENETICS to Participate in Fireside Chat at Barclays Global Healthcare ConferenceBOSTON and LAUSANNE, Switzerland, March 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a leader in data-driven medicine, announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16 at 11:15 a.m. ET/5:15 p.m. CET at the Loews Miami Beach Hotel in Miami, FL, United States. A live webcast and replay of the session will be available on the investor relations section of the SOPHiA GENETICS website at https://ir.sophiagenetics.com. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a healthcare technology company dedicated to establishing the practice of da
- SOPHiA GENETICS to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Officer Ross Muken, will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. The virtual presentation will begin at 8:15 a.m. ET/2:15 p.m. CET on Tuesday, January 11, 2022 and will be available live and archived on SOPHiAGENETICS.COM, in the Investor Relations section. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. I
- SOPHiA GENETICS to Participate in Upcoming November Investor ConferencesBOSTON and LAUSANNE, Switzerland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH) today announced the company will be participating virtually in the following investor conferences: Credit Suisse 30th Annual Healthcare Conference; Fireside Chat on Thursday, November 11th at 2:40pm ET / 8:40pm CETPiper Sandler 33rd Annual Healthcare Conference; Presentation available on demand beginning November 22nd at 10:00am ET / 4:00pm CETEvercore ISI HealthCONx Conference; Fireside Chat on Tuesday, November 30th at 8:00am ET / 2:00pm CET Interested parties may access live and archived webcasts of the presentations on the "Investors" section of the company website at ir.sophiagenetic
- SOPHiA GENETICS to Present at the Morgan Stanley 19th Annual Global Healthcare ConferenceBOSTON and LAUSANNE, Switzerland, Aug. 30, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. SOPHiA GENETICS' management is scheduled to present on Friday, September 10th at 9:30 a.m. Eastern Time/3:30 p.m. Central European Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: ir.sophiagenetics.com. About SOPHiA GENETICS SOPHiA GENETICS (NASDAQ:SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care a